

**CURRICULUM VITAE**  
**Robert S. Williams, M.D.**

PRESENT POSITION

Urology Associates, LLC  
2525 W. University Ave.  
Suite 504  
Muncie, IN 47303  
Phone: (765) 289-7444  
Fax: (765) 289-8628  
1989-present

Cancer Committee Member  
Cancer Center  
Ball Memorial Hospital  
2401 W. University Ave.  
Muncie, IN 47303  
1991-present

Director  
Indiana Continence Center  
Muncie, IN  
1995-present

Active Clinical Staff  
Ball Memorial Hospital  
2401 W. University Ave.  
Muncie, IN 47303  
1989-present

UNDERGRADUATE EDUCATION

Miami University  
Oxford, OH  
BS in Chemistry  
1976-1980

MEDICAL EDUCATION

Indiana University School of Medicine  
Indianapolis, IN  
MD, AOA

GRADUATE MEDICAL EDUCATION

University of Tennessee

Memphis, TN  
Urology under Dr. Soloway and Dr. Cox  
1984-1989

CERTIFICATION

American Board of Urology  
1991

Recertification  
1999

PROFESSIONAL AFFILIATIONS

American Urologic Association  
American Association of Clinical Urologists  
American Medical Association  
Indiana State Medical Association

RESEARCH EXPERIENCE

|                              |  |
|------------------------------|--|
| 1986-1989                    | Phase II and III antibiotics trials under Dr. C.E. Cox at the University of Tennessee. Numerous trials including Cipro and Floxin.   |
| ILEX Oncology, Inc.          | Phase III Randomized, Double-Blind Study of DFMO vs. Placebo in Low Grade Superficial Bladder Cancer.  |
| Warner Chilcott Laboratories | Urogenital Investigation with Estrace Cream. A Phase IV, Open-Label, Multicenter, Community-Based Trial of Estrace Cream for the Treatment of Urogenital Symptoms in Postmenopausal Women. |
| Schering                     | A Multicenter Trial of Induction and 6 courses of 3 week Maintenance with BCG Versus BCG Plus Interferon Alpha-2b (Intron A) in Superficial Bladder Cancer                                 |
| Novartis                     | Protocol #CZOL446EUS24: An Open-Label Trial on the Effect of IV Zometa 4 mg. on Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients with Bone Metastasis                    |

Novartis Protocol CZOL446G US45: The Effect of Zometa Compared to Placebo on Bone Mineral Density in Patients Undergoing Androgen Deprivation Therapy. Zenith Trial (CZOL446G US45)

Hoosier Oncology Group/  
CATO Protocol GU02-41. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients with Metastatic Prostate Cancer Commencing Hormonal Therapy.

AMGEN Protocol 20040138: A Randomized, Double-Blind, Placebo-controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer (HALT)

YAMANOUCHI Protocol 905-UC-006: An Open-Label Study Multicenter Study to Assess The Efficacy and Safety of Daily Oral Administration of 5 and 10 mg Vesicare<sup>®</sup> (Solifenacin Succinate) in Patients Who Wish to Switch from Detrol LA<sup>®</sup> (Tolterodine Tartrate Extended Release) for the Treatment of Overactive Bladder Symptoms (VERSUS)

#### PUBLICATIONS

Long-Term Effects of Polytetrafluoroethylene Injected into the Rat Bladder's Submucosa. Urology. June, 1994.

Initial Results of Gax Collagen for the Treatment of Intrinsic Sphincter Dysfunction in the Community. Urology. December, 1995.

---

Robert S. Williams, M.D.

---

Date